Abstract:Background: The potential factors beyond HbA1c that increase the risk of cardiovascular disease and age more quickly in people with diabetes are not yet clear. This study sought to determine the prospective associations between discrepancies in observed and predicted HbA1c levels, also known as the hemoglobin glycation index (HGI), and cardiovascular disease risk. Additionally, the interactions of HGI with accelerated aging in relation to cardiovascular disease risk were evaluated. Method: This cross-sectional study included 9167 adults from the National Health and Nutrition Examination Survey 1999-2010. The HGI is used to assess individual blood glucose variability, and phenotypic age acceleration is employed to evaluate accelerated aging. Regression analysis, restricted cubic spline and mediation analysis explore the potential roles of phenotypic age acceleration in the relationship between HGI and CVD mortality. Results: Among the 9167 eligible participants (aged 20 years or older), 4390 (47.9%) were males, and the median (IQR) age was 48.0 (15.0) years; 4403 (48.0%) had prediabetes and diabetes, and 985 (10.7%) had cardiovascular disease. Restricted cubic splines showed that the association between HGI and CVD risk was nonlinear (p < 0.001). The greater the negative value of the HGI was, the greater the risk of CVD, and the association was independent of age, sex and HbA1c. Mediation analyses confirmed that phenotypic age acceleration acted as a mediator in the association between HGI and CVD risk (mediated effect: OR, 68.7%, 95% CI: 36.4%-153%, P=0.002). Conclusion and Relevance: The HGI serves as a robust biomarker for assessing the acceleration of aging, regardless of HbA1c levels, and is associated with increased susceptibility to cardiovascular disease, particularly among individuals characterized by negative HGI.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the relationship between the Hemoglobin Glycation Index (HGI) and the risk of Cardiovascular Disease (CVD), and whether this relationship is mediated by Aging Acceleration. Specifically, the researchers hope to determine the prospective association between HGI and CVD risk, and evaluate the interaction between HGI and Aging Acceleration in CVD risk. ### Research Background - **Diabetes and Cardiovascular Disease**: Type 2 diabetes (T2D) and pre - diabetes are common in patients with cardiovascular diseases and are associated with adverse cardiovascular outcomes. - **Limitations of HbA1c**: Although HbA1c can partially indicate the risk of cardiovascular diseases, it cannot fully reflect blood - glucose control, especially in about 40% of diabetic patients. - **Significance of HGI**: HGI reflects the differences in individual blood - glucose variability and may be used as an indicator to assess vascular health status, which is related to the risk of multiple diabetic vascular complications. ### Research Objectives - **Primary Objective**: To study the relationship between HGI and CVD risk, and the mediating role of Aging Acceleration in this relationship. - **Hypothesis**: The researchers hypothesize that Aging Acceleration may be an important mediating factor between HGI and CVD risk. ### Research Methods - **Data Source**: Use the data from the National Health and Nutrition Examination Survey (NHANES) in the United States from 1999 - 2010. - **Sample Selection**: Finally, 9,167 adults were included for analysis. - **Variable Definition**: - **HGI**: Calculated by observing the difference between HbA1c and predicted HbA1c. - **Aging Acceleration**: Evaluated by Phenotypic Age Acceleration (PAA). - **CVD**: Determined by questionnaire survey. - **Statistical Analysis**: Use multiple linear regression and logistic regression models, as well as Restricted Cubic Splines and mediation analysis to explore the relationships between HGI, PAA and CVD risk. ### Main Findings - **Relationship between HGI and CVD Risk**: There is a non - linear relationship between HGI and CVD risk. The more negative the value, the higher the CVD risk, and this relationship is independent of age, gender and HbA1c level. - **Mediating Role of Aging Acceleration**: PAA plays a mediating role in the relationship between HGI and CVD risk, and the mediating effect is 68.7% (95% CI: 36.4% - 153%, P = 0.002). ### Conclusions - **HGI as a Biomarker**: HGI is a powerful biomarker that can assess Aging Acceleration, is independent of HbA1c level, and is associated with increased susceptibility to cardiovascular diseases, especially in individuals with negative HGI. - **Clinical Significance**: HGI can be used as a convenient tool to monitor the risk of cardiovascular diseases, especially in patients with pre - diabetes or diabetes. ### Formula - **Calculation formula of Phenotypic Age**: \[ \text{Phenotypic Age} = 141.50+\frac{\ln[- 0.00553\times\ln(\exp(-1.51714\times\exp(x_b)))]}{0.076927} \] where \[ x_b=-19.907 - 0.0336\times\text{Albumin}+0.0095\times\text{Creatinine}+0.1953\times\text{Glucose}+0.0954\times\ln(CRP)-0.0120\times\text{Lymphocyte Percent}+0.0268\times\text{Mean Cell Volume}+0.3306\times \]

Is aging acceleration mediating the association between hemoglobin glycation index and cardiovascular disease?

Accelerated Aging Mediates the Associations of Unhealthy Lifestyles with Cardiovascular Disease, Cancer, and Mortality.

Hemoglobin Glycation Index Is Associated With Cardiovascular Diseases in People With Impaired Glucose Metabolism

Association Between Glucose Metabolism and Vascular Aging in Chinese Adults: A Cross-Sectional Analysis in the Tianning Cohort Study.

Sex‐specific associations between haemoglobin glycation index and the risk of cardiovascular and all‐cause mortality in individuals with pre‐diabetes and diabetes: A large prospective cohort study

Association of Hemoglobin Glycation Index and Glycation Gap with Cardiovascular Disease among US Adults

Association of the hemoglobin glycation index with cardiovascular and all-cause mortality in individuals with hypertension: findings from NHANES 1999–2018

Hemoglobin glycation index and cardiovascular outcomes in patients with diabetes and coronary artery disease: insights from a large cohort study

Associations between glycated haemoglobin and multi-modal imaging markers of early cardiac aging

Association Between Hemoglobin Glycation Index and 5-Year Major Adverse Cardiovascular Events: the REACTION Cohort Study.

Age - a Significant Independent Factor of A1C Levels. Evidence from the National Health and Nutrition Examination Survey 1999-2014.

Association of haemoglobin glycation index with all-cause and cardiovascular disease mortality in diabetic kidney disease: a cohort study

Factors influencing accelerated aging in patients with type 2 diabetes mellitus and coronary heart disease

Association between hemoglobin glycation index and subclinical myocardial injury in the general population free from cardiovascular disease

The hemoglobin glycation index predicts the risk of adverse cardiovascular events in coronary heart disease patients with type 2 diabetes mellitus

Associations of combined accelerated biological aging and genetic susceptibility with incidence of heart failure in a population‐based cohort study

Glycated haemoglobin index is a new predictor for all-cause mortality and cardiovascular mortality in the adults

Long-term Risks for Cardiovascular Disease and Mortality Across the Glycaemic Spectrum in a Male-Predominant Chinese Cohort Aged 75 Years or Older: the Kailuan Study.

Effects of the hemoglobin glycation index on hyperglycemia diagnosis: Results from the REACTION study

Importance of the Hemoglobin Glycation Index for Risk of Cardiovascular and Microvascular Complications and Mortality in Individuals with Type 2 Diabetes

Epigenetic Age Acceleration Reflects Long-Term Cardiovascular Health